B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

(2016) Barbara Kiesewetter et al.   BLOOD

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group

(2016) Alejandro Martín et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

(2016) Marek Trněný et al.   LANCET ONCOLOGY

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study

(2016) Dongmei Ji et al.   Oncotarget

Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread

(2015) Ping-Pui Wong et al.   CANCER CELL

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

(2015) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

(2015) Grzegorz S. Nowakowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

(2015) Jia Ruan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor angiogenesis, from foe to friend

(2015) L. B. Rivera et al.   SCIENCE

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

(2014) Joseph M. Tuscano et al.   BRITISH JOURNAL OF HAEMATOLOGY

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma

(2014) Tatyana Feldman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

(2014) Zhiying Fu et al.   Cancer Cell International

Programmed Translational Readthrough Generates Antiangiogenic VEGF-Ax

(2014) Sandeepa M. Eswarappa et al.   CELL

Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases

(2014) A. Guidetti et al.   CLINICAL CANCER RESEARCH

Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma

(2014) John D. Hainsworth et al.   Clinical Lymphoma Myeloma & Leukemia

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial

(2014) S. Riihijarvi et al.   HAEMATOLOGICA

Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma

(2014) Hiroki Goto et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

(2014) Umberto Vitolo et al.   LANCET ONCOLOGY

An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

(2014) Soo Jeong Nam et al.   LEUKEMIA & LYMPHOMA

Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases

(2014) Pavla Veselá et al.   VIRCHOWS ARCHIV

Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes

(2013) J. Ruan et al.   BLOOD

Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

(2013) K. Song et al.   CANCER RESEARCH

Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results

(2013) Jia Ruan et al.   Clinical Lymphoma Myeloma & Leukemia

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

(2013) Andre Goy et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

(2013) Daniel R Greenwald et al.   Journal of Hematology & Oncology

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

(2013) M Wang et al.   LEUKEMIA

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma

(2013) Danielle Brander et al.   LEUKEMIA & LYMPHOMA

High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma

(2013) Antonio Rueda et al.   LEUKEMIA & LYMPHOMA

Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

(2013) Carmelo Carlo-Stella et al.   PLoS One

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515

(2012) A. T. Stopeck et al.   BLOOD

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

(2012) Heather E. Eve et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase II study of sorafenib in patients with relapsed or refractory lymphoma

(2012) Anna Guidetti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma

(2012) S. Xargay-Torrent et al.   CLINICAL CANCER RESEARCH

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

(2012) Sari Riihijärvi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

(2012) Michael Wang et al.   LANCET ONCOLOGY

Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model

(2012) F Mori et al.   Blood Cancer Journal

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

(2011) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation

(2011) Bjoern Chapuy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

(2011) Francisco J. Hernandez-Ilizaliturri et al.   CANCER

Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma

(2011) Martha Romero et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy

(2011) T. M. Cardesa-Salzmann et al.   HAEMATOLOGICA

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

(2011) G S Nowakowski et al.   LEUKEMIA

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

(2011) Rena Buckstein et al.   LEUKEMIA & LYMPHOMA

Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma

(2010) Hanan AlSaeid Alshenawy   Annals of Diagnostic Pathology

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

(2010) Jia Ruan et al.   CANCER

Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy

(2010) Minna Taskinen et al.   EUROPEAN JOURNAL OF CANCER

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

(2010) Tait Shanafelt et al.   LEUKEMIA & LYMPHOMA

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

(2009) Liang Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival

(2009) Sana Intidhar Labidi et al.   ANNALS OF HEMATOLOGY

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation

(2009) P. Farinha et al.   BLOOD

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)

(2009) Dita Gratzinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

(2009) Thomas E. Witzig et al.   JOURNAL OF CLINICAL ONCOLOGY

High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma

(2009) Joaquim Carreras et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

(2009) A. Craig Lockhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas

(2009) Judit M. Jørgensen et al.   LEUKEMIA & LYMPHOMA

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

(2009) Alison T. Stopeck et al.   LEUKEMIA & LYMPHOMA

Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma

(2008) J. Ruan et al.   ANNALS OF ONCOLOGY

Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP

(2008) M. Taskinen et al.   BLOOD

Thalidomide for treatment of multiple myeloma: 10 years later

(2008) A. Palumbo et al.   BLOOD

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis

(2008) Na-Ri Lee et al.   LEUKEMIA & LYMPHOMA

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

(2007) Danielle Canioni et al.   JOURNAL OF CLINICAL ONCOLOGY